ReviewTranslational research : the journal of laboratory and clinical medicine2019
siRNA- and miRNA-based therapeutics for liver fibrosis.
Review in Translational research : the journal of laboratory and clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 103 citations in OpenAlex.
- Bovine Milk-Derived Extracellular Vesicles as Emerging Drug Delivery Platforms: Current Advances, Applications and Challenges.Journal of extracellular biology · 2026Review
- Fibrotic microRNAs in the suppression of HSC activation and ECM deposition to facilitate the regression of hepatic fibrosis in zebrafish.Journal of molecular medicine (Berlin, Germany) · 2026Article
- Identification of CCND1 and IL7R as core JAK-STAT pathway genes promoting hepatitis B-related liver fibrosis.Frontiers in immunology · 2026Article
- Genomic medicine in hepatology: mechanisms and liver treatment strategies.Molecular medicine (Cambridge, Mass.) · 2025Review
- Biomimetic nanoparticles for targeted therapy of liver disease.RSC pharmaceutics · 2025Review
- miR-29b-3p Affects the Hypertrophy of Ligamentum Flavum in Lumbar Spinal Stenosis and its Mechanism.Biochemical genetics · 2025Article
- miR-372-3p represses hepatic stellate cell activation via the RhoC/ROCK pathway.Cytotechnology · 2025Article
- Immunology and treatments of fatty liver disease.Archives of toxicology · 2025Review
- Sinusoidal communication in chronic liver disease.Clinical and molecular hepatology · 2025Review
- Research and application of medicines for treating liver fibrosis: current status and prospects.Frontiers in pharmacology · 2025Review
- Food plants as adjuvant medicines: a review of protective effects and clinical potential in alcoholic liver disease.Frontiers in pharmacology · 2025Review
- Study on the Hepatotoxicity of Emodin and Its Application in the Treatment of Liver Fibrosis.Molecules (Basel, Switzerland) · 2024Article
- Liver fibrosis pathologies and potentials of RNA based therapeutics modalities.Drug delivery and translational research · 2024Review
- Development of a Lipid-encapsulated TGFβRI-siRNA Drug for Liver Fibrosis Induced by Schistosoma mansoni.PLoS neglected tropical diseases · 2024Article
- MicroRNA-582-3p knockdown alleviates non-alcoholic steatohepatitis by altering the gut microbiota composition and moderating TMBIM1.Irish journal of medical science · 2024Article
- Effects of nicotine on microRNA-124 expression in bile duct ligation-induced liver fibrosis in rats.BMC pharmacology & toxicology · 2024Article
- miR-26a is a Key Therapeutic Target with Enormous Potential in the Diagnosis and Prognosis of Human Disease.Current medicinal chemistry · 2024Review
- Nanoparticles for Creating a Strategy to Stimulate Liver Regeneration.Sovremennye tekhnologii v meditsine · 2024Article
- Anti-Liver Fibrosis Role of miRNA-96-5p via Targeting FN1 and Inhibiting ECM-Receptor Interaction Pathway.Applied biochemistry and biotechnology · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Liver fibrosis is a wound-healing process induced by chronic liver injuries, such as nonalcoholic steatohepatitis, hepatitis, alcohol abuse, and metal poisoning. The accumulation of excessive extracellular matrix (ECM) in the liver is a key characteristic of liver fibrosis. Activated hepatic stellate cells (HSCs) are the major producers of ECM and therefore play irreplaceably important roles during the progression of liver fibrosis. Liver fibrogenesis is highly correlated with the activation of HSCs, which is regulated by numerous profibrotic cytokines. Using RNA interference to downregulate these cytokines in activated HSCs is a promising strategy to reverse liver fibrosis. Meanwhile, microRNAs (miRNAs) have also been exploited for the treatment of liver fibrosis. This review focuses on the current siRNA- and miRNA-based liver fibrosis treatment strategies by targeting activated HSCs in the liver.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.